The biological feasibility and social context of gene-edited, caffeine-free coffee

被引:0
|
作者
Nils V. Leibrock
Joris Santegoets
Paul J. W. Mooijman
Filemon Yusuf
Xander C. L. Zuijdgeest
Esmée A. Zutt
Josette G. M. Jacobs
Jan G. Schaart
机构
[1] Wageningen University and Research,Programme Molecular Life Sciences
[2] Wageningen University and Research,Programme Plant Sciences
[3] Wageningen University and Research,Programme Plant Biotechnology
[4] Wageningen University and Research,Programme Biology
[5] Wageningen University and Research,Philosophy
[6] Wageningen University and Research,Plant Breeding
来源
关键词
CRISPR-Cas; Genetic modification; XMT; DXMT; MXMT; Caffeine pathway;
D O I
暂无
中图分类号
学科分类号
摘要
Coffee, especially the species Coffea arabica and Coffea canephora, is one of the world’s most consumed beverages. The consumer demand for caffeine-free coffee is currently being met through chemical decaffeination processes. However, this method leads to loss of beverage quality. In this review, the feasibility of using gene editing to produce caffeine-free coffee plants is reviewed. The genes XMT (7-methylxanthosine methyltransferase) and DXMT (3,7-dimethylxanthine methyltransferase) were identified as candidate target genes for knocking out caffeine production in coffee plants. The possible effect of the knock-out of the candidate genes was assessed. Using Agrobacterium tumefaciens-mediated introduction of the CRISPR-Cas system to Knock out XMT or DXMT would lead to blocking caffeine biosynthesis. The use of CRISPR-Cas to genetically edit consumer products is not yet widely accepted, which may lead to societal hurdles for introducing gene-edited caffeine-free coffee cultivars onto the market. However, increased acceptance of CRISPR-Cas/gene editing on products with a clear benefit for consumers offers better prospects for gene editing efforts for caffeine-free coffee.
引用
收藏
页码:635 / 655
页数:20
相关论文
共 22 条
  • [21] Generation of HIV-1-infected patients' gene-edited induced pluripotent stem cells using feeder-free culture conditions
    Ye, Lin
    Wang, Jiaming
    Teque, Fernando
    Xie, Fei
    Tan, Yuting
    Kan, Yuet Wei
    Levy, Jay A.
    AIDS, 2020, 34 (08) : 1127 - 1139
  • [22] A phase Ia/Ib, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors.
    Chmielowski, Bartosz
    Ejadi, Samuel
    Funke, Roel
    Stalligs-Schmitt, Todd
    Denker, Mitch
    Frohlich, Mark Walter
    Franzusoff, Alexis J.
    Abedi, Mehrdad
    Cristea, Mihaela C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)